...
首页> 外文期刊>Stem Cell Studies >Stem cell therapy for refractory angina
【24h】

Stem cell therapy for refractory angina

机译:干细胞治疗难治性心绞痛

获取原文
           

摘要

Stem cells (SC) have demonstrated significant potential for regeneration of ischemic myocardium in both animals and humans, primarily after acute myocardial infarction. Recently, SC therapy for unstable angina pectoris, to include intractable chest pain and non-revascularizable coronary disease, has displayed clinical benefit within this subset of patients that are often refractory to medical therapy and poor candidates for reperfusion strategies, and thereby urgent need for novel therapies. Few human clinical trials have been completed to date with positive yet variable results due to inconsistencies in trial design rendering them difficult to interpret for clinical practice. Herein, a summary of all clinical trials of SC therapy in refractory angina is provided with pertinent findings from each study.
机译:干细胞(SC)已证明在动物和人类中都有重要的再生缺血性心肌的潜力,主要是在急性心肌梗塞后。近来,SC治疗不稳定型心绞痛的方法包括难治性胸痛和不可血管重建的冠心病,已在这部分患者中显示出临床益处,这些患者通常对药物治疗无效,并且对于再灌注策略的候选人也不多,因此迫切需要新型疗法。迄今为止,由于试验设计的不一致,很少有人类临床试验能够取得积极而可变的结果,这使得它们难以为临床实践解释。在此,对难治性心绞痛的SC治疗的所有临床试验进行了总结,并提供了每项研究的相关发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号